期刊文献+

人肥大细胞系白细胞介素4的产生及药物对其的影响 被引量:3

Effects of budesonide, desloratadine and dexamethasone on interleukine-4 release and expression from human mast cell line
原文传递
导出
摘要 目的了解人肥大细胞系(humanmastcellline,HMC1)在佛波醇酯(phorbol12myristate13acetate,PMA)+钙离子通道(A23187)激发下能否产生白介素(Interleukin,IL)4,并且观察布地奈得、地氯雷他定和地塞米松等药物对IL4的产生和表达的影响。方法HMC1在10-6~10-10mol/L浓度的药物中孵育1h后,以25ng/mlPMA+25×10-7mol/LA23187激发细胞因子生成,再分别孵育6、12或24h,提取上清液,采用酶联免疫吸附法(enzymelinkedimmunosorbentassays,ELISA)测定IL4水平,并采用半定量逆转录聚合酶链反应(reversetranscriptionpolymerasechainreaction,RTPCR)观察药物对IL4mRNA表达水平的影响。结果HMC1在激发后可产生IL4,IL4mRNA的表达也很明显。布地奈得、地氯雷他定和地塞米松在各时间点和浓度下,均对HMC1IL4的产生有明显的抑制作用(同未加药物的对照组比较,P值均<005),抑制率在(361±40)%到(679±38)%之间。布地奈得和地塞米松对IL4mRNA的表达无抑制作用,而地氯雷他定则能明显抑制IL4mRNA的表达水平。结论HMC1经激发可表达和产生IL4,布地奈得、地氯雷他定和地塞米松能显著抑制IL4的产生,地氯雷他定还能抑制IL4mRNA的表达。 Objective Since human mast cell is an important source of cytokines, it is of importance to understand the effects of anti-allergic drugs on cytokines modulation in mast cells. In the present study, we aimed at observing whether IL-4 could be released from human mast cell line (HMC-1) after the stimulation of PMA+A23187, and the effects of systemic glucocorticosteroid, dexamethasone, topical glucocorticosteroid, budisonide and H1 antagonist, desloratadine on IL-4 release and mRNA expression. Methods HMC-1 was stimulated with 25 ng/ml phorbol 12-myristate 13-acetate (PMA) and 2.5× 10^-7 mol/L ionomycin (A23187) and cultured for 6 hours, 12 hours and 24 hours respectively in the presence or absence of 10^-6 -10^-10 mol/L concentrations of test drugs. Culture supernatants were collected and the levels of IL-4 were assayed by enzyme-linked immunosorbent assays (ELISA). The mRNA expression of IL-4 was measured by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR). Results HMC-1 expressed IL-4 mRNA and the resulting protein production of IL-4 released after being stimulated with PMA plus A23187. Dexamethasone, budesonide and desloratadine had potent inhibitory effect on IL-4 release at any concentrations and time points, with significant deference (P<0.05) compared to the control cells. The inhibitory effect did not show time-dependent and concentration-dependent manner. Desloratadine and budesonide showed neither up-regulatory nor down-regulatory effects on IL-4 mRNA expression at the test concentrations, however, desloratadine could down-regulate IL-4 mRNA expression. Conclusions HMC-1 could express and produce IL-4 after stimulation. Dexamethasone, budesonide and desloratadine all had inhibitory effects on IL-4 release from HMC-1.In addition, desloratadine could also inhibit the IL-4 mRNA expression.
出处 《中华耳鼻咽喉头颈外科杂志》 CAS CSCD 北大核心 2005年第2期124-127,共4页 Chinese Journal of Otorhinolaryngology Head and Neck Surgery
关键词 肥大细胞系 白细胞介素4 地氯雷他定 地塞米松 Mast cells Cell culture Interleukin-4
  • 相关文献

参考文献12

  • 1Moller A, Henz BM, Grutzkau A, et al. Comparative cytokine gene expression: regulation and release by human mast cells. Immunology, 1998,93:289-295.
  • 2Lippert U, Kruger-Krasagakes S, Moller A, et al. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol, 1995,4:272-276.
  • 3Lippert U, Moller A, Welker P, et al. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol, 2000,9:118-124.
  • 4Butterfield JH, Weiler D, Dewald G,et al. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res, 1988,12:345-355.
  • 5Krishnaswamy G, Lakshman T, Miller AR, et al. Multifunctional cytokine expression by human mast cells: regulation by T cell membrane contact and glucocorticoids. J Interferon Cytokine Res, 1997,17:167-176.
  • 6Marone M, Mozzetti S, De Ritis D, et al. Semiquantitative RT-PCR analysis to assess the expression levels of multiple transcripts from the same sample. Biol Proced Online, 2001,3:19-25.
  • 7Yamamura M, Uyemura K, Deans RJ, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science, 1991,254:277-279.
  • 8Weber S, Babina M, Kruger-Krasagakes S, et al. A subclone (5C6) of the human mast cell line HMC-1 represents a more differentiated phenotype than the original cell line. Arch Dermatol Res, 1996,288:778-782.
  • 9Del Prete GF, De Carli M, Mastromauro C, et al. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest, 1991,88:346-350.
  • 10Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature, 1996,383:787-793.

同被引文献42

  • 1曾凡锁,詹亚光.转基因植物中外源基因的整合特性及其研究策略[J].植物学通报,2004,21(5):565-577. 被引量:23
  • 2王艳杰,申家恒.花粉管通道法转基因技术的细胞胚胎学机理探讨[J].西北植物学报,2006,26(3):628-634. 被引量:26
  • 3Bachert C, van Cauwenberge P. Desloratadine treatment for interrnittent and persistent allergic rhinitis: a review [J]. Clin Ther, 2007, 29 (9): 1795-1802.
  • 4Orzechowski RF, Currie DS, Valancius CA. Comparative anti-cholinergic activities of 10 histamine HI receptor antagonists in two functional models [J]. Eur J Pharmacol, 2005, 506 (3): 257- 264.
  • 5Pradalier A, Neukirch C, Dreyfus I, et al. Desloratadine im proves quality of life and symptom severity in patients with allergic rhinitis [J]. Allergy, 2007, 62 (11): 1331- 1334.
  • 6Ortonne JP, Grob JJ, Auquier P, et al. Efficacy and safety of Desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo controlled, multicenter trial [J]. AmJ ClinDermatoh 2007, 8 (1): 37-42.
  • 7Gillman S, Gillard M, Benedetti M. The concept of receptor occupancy to predict clinical efficacy: A comparison of second generation H1 antihistamines [J].Allergy Asthma Proc, 2009, 30 (10): 350-354.
  • 8Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of Desloratadine, fexofenadine and levocetirizine : a comparative review[J]. Clin Pharmacokinet, 2008, 47 (4): 217- 230.
  • 9Anthes JC, Gilehrest H, Richard C, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H (1)receptor [J]. EurJ Pharmacol, 2002, 449 (3): 229-237.
  • 10Gillard M, Chatelain P. Changes in pH differentIy affect the binding properties of histamine H1 receptor antagonists [J]. Eur J Pharmacol, 2006, 530 (3): 205 -214.

引证文献3

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部